Fabrinet (FN) reported robust Q4 results, with earnings of $2.65 per share surpassing the Zacks Consensus Estimate of $2.64 and revenues reaching $909.69 million, exceeding estimates by 3.01% and marking significant year-over-year growth. The company has consistently beaten revenue estimates over the past four quarters and EPS in three of the last four, contributing to its stock's approximately 50% year-to-date gain, significantly outperforming the S&P 500. With a favorable earnings estimate revision trend and a Zacks Rank #2 (Buy), the stock is anticipated to continue its strong performance, supported by a positive industry outlook.
Fabrinet (FN) delivered a strong fourth-quarter performance, exceeding analyst expectations on both top and bottom lines. The company reported adjusted earnings of $2.65 per share, narrowly beating the consensus estimate of $2.64 and representing a 9.9% increase from the $2.41 per share earned a year ago. Revenue performance was more pronounced, with the $909.69 million figure surpassing consensus by 3.01% and marking a significant 20.8% year-over-year increase from $753.26 million. This result continues a consistent trend of operational outperformance, as the company has now topped revenue estimates for four consecutive quarters. This fundamental strength has been recognized by the market, with Fabrinet's shares appreciating approximately 50% year-to-date, substantially outpacing the S&P 500's 9.7% gain. Looking forward, the stock carried a favorable Zacks Rank #2 (Buy) heading into the report, supported by a positive trend in earnings estimate revisions and a solid industry backdrop, with its sector ranking in the top 39% of over 250 industries. However, the sustainability of its recent share price momentum will be highly dependent on management's forward-looking commentary provided during its earnings call.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.80
Ticker Sentiment